Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 10/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 9/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 9/20 | 0.35 |
| ▸ | FAP | Q12884 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8751922 | 0.86 | DPP4 (0.42) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL22890984 | 0.86 | DPP4 (0.42) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL21985751 | 0.83 | DPP4 (0.40) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL1982494 | 0.81 | LMNA (0.32) | — | |
| SCHEMBL21105595 | 0.80 | DPP4 (0.43) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL7779225 | 0.80 | DPP4 (0.43) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL7779224 | 0.80 | DPP4 (0.43) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL3194064 | 0.79 | DPP4 (0.37) | DPP4DPP8DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL16007456 | 0.79 | DPP4 (0.42) | DPP4DPP8DPP9DPP7 | |
| Hydrochloric Acid SCHEMBL11122949 | 0.79 | DPP4 (0.42) | DPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10414800-B2 | Methods for producing a depsipeptide | NOVOBIOTIC PHARMACEUTICALS, LLC (US) | 2019-09-17 | — | — | US | disclosed |
| US-20170121372-A1 | NOVEL DEPSIPEPTIDE AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121372-A1 | NOVEL DEPSIPEPTIDE AND USES THEREOF | VIP, DPP7, DNPEP | DPP4 8/4885DPP8 6/4885DPP9 10/4885 |
| US-10414800-B2 | Methods for producing a depsipeptide | VIP, DNPEP, PSAP | DPP4 14/4885DPP8 12/4885DPP9 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.